Ignite Creation Date:
2025-12-24 @ 4:27 PM
Ignite Modification Date:
2026-01-07 @ 4:53 AM
Study NCT ID:
NCT05325866
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-01
First Post:
2022-04-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Sponsor:
Amgen
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-23
Start Date Type:
ACTUAL
Primary Completion Date:
2026-02-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-02-06
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-06
First Submit QC Date:
None
Study First Post Date:
2022-04-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-29
Last Update Post Date:
2025-10-01
Last Update Post Date Type:
ESTIMATED